Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study
Abstract
This study aimed to elucidate how sodium-glucose cotransporter 2 (SGLT2) inhibitors and sulfonylureas differentially modulate hepatic metabolism in persons with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). In this 48-week randomized, open-label, parallel-group trial, Japanese participants with type 2 diabetes and biopsy-confirmed MASLD received either tofogliflozin or glimepiride. Paired liver biopsy samples and serum were collected at baseline and after 48 weeks. We performed a post hoc metabolomic analysis to assess hepatic and systemic metabolic shifts and their correlations with histological and clinical parameters. Tofogliflozin treatment significantly increased hepatic glucose 1-phosphate and acetyl-CoA levels, reflecting a metabolic shift toward ketogenesis and gluconeogenesis. Regarding TCA cycle intermediates, tofogliflozin elevated serum citrate but reduced serum succinate; notably, the reduction in succinate correlated with reduction in liver enzyme levels. Furthermore, higher baseline serum succinate predicted superior histological improvements (ballooning and inflammation) in the tofogliflozin group. In contrast, glimepiride specifically reduced hepatic branched-chain amino acids (BCAAs), which was associated with decreased steatosis. Tofogliflozin also elevated serum urea cycle intermediates, suggesting a distinct "aestivation-like" response to hypovolemia. The metabolic signature of SGLT2 inhibitors in the human…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.